Clearance Summary
Smith+Nephew INTELLIO Tablet received FDA 510(k) clearance under submission number K221929, sponsored by Smith+Nephew. The device was reviewed via the Traditional premarket notification pathway and assigned to the Gastroenterology, Urology review panel. The statutory decision date of record is 2022-09-06.
- Submission: K221929
- Applicant / Sponsor: Smith+Nephew
- Clearance pathway: Traditional
- Review panel: Gastroenterology, Urology
- Device class: Class II
- Regulation citation: 21 CFR 876.1500
- Decision date: 2022-09-06
Classification & Regulation
This clearance is catalogued under FDA product code ODA and 21 CFR 876.1500, within the Gastroenterology, Urology review panel as a Class II device.